NextGen Scientific LLC today issued an updated announcement to supersede and replace a previously distributed press release, which contained inaccurate information regarding the structure and use of proceeds of the company’s current capital raise. This updated release reflects the correct and complete details of NextGen Scientific’s $10 million Regulation D, Rule 506(c) private placement offering to accredited investors.
NextGen Scientific is raising $10 million from accredited investors in a Regulation D, Rule 506(c) private placement offering. Proceeds from the offering will be used to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries, including Genzada Pharmaceuticals USA and Hyatt Life Sciences.
Genzada Pharmaceuticals USA is an early-stage biotechnology company focused on oncology drug development, with two clinical-stage drug candidates and additional assets in development. GZ17-6.02, an oral compound, has demonstrated safety and efficacy in preclinical and clinical studies and is currently being evaluated in a metastatic prostate cancer study at Virginia Commonwealth University. GZ21T, a topical therapy for cancerous and precancerous skin conditions, is expected to receive regulatory approval in Q1 2026 to initiate a Phase 1b/2a clinical trial in actinic keratosis patients in Sweden and the Netherlands. Capital raised will primarily support clinical and preclinical programs for GZ17-6.02 and GZ21T, as well as related drug manufacturing and development activities.
Hyatt Life Sciences is a revenue-generating nutraceutical and botanical sciences enterprise specializing in science-based dietary supplements. Hyatt integrates traditional botanical knowledge with modern scientific validation and operates within the rapidly expanding global nutraceuticals market.
“During our Phase I dose escalation study for GZ17-6.02, we observed promising biological effect against a broad array of cancer types and we are excited to further explore how this translates into meaningful clinical impact,” says the Company’s Chief Operating Officer Cameron West, MD, FAAD. “In addition, based on the significant body of preclinical data and the promising preliminary safety profile of GZ21T, I am optimistic that it has the potential to deliver game changing results in a multitude of dermatologic conditions.”
Investors in the offering gain exposure to both clinical-stage drug development and a growing, revenue-generating, science-driven nutritional supplements business. Proceeds will primarily support clinical studies of GZ21T in atopic dermatitis, pre-clinical advancement, and the clinical and pre-clinical development of GZ17-6.02 for prostate and breast cancer, along with drug manufacturing activities and targeted marketing initiatives for the Company’s supplement portfolio.
NextGen Scientific is a life sciences company focused on advancing oncology and dermatology drug development while participating in the commercialization of science-backed wellness products. Through its strategic investment in Ionics Life Sciences and its subsidiaries, NextGen is building a diversified healthcare platform designed to generate long-term value through clinical innovation and active revenue streams. Learn more at investinnextgen.com.
